- ISIN
- US88322Q1085
- CUSIP
- 88322Q108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 14, 1995
Highlights
- Market Cap
- $8.71B
- Enterprise Value
- $8.28B
- EPS (TTM)
- $2.87
- PE Ratio
- 18.93
- PEG Ratio
- 0.03
- Total Revenue (TTM)
- $700.35M
- Gross Profit (TTM)
- $581.54M
- EBITDA (TTM)
- $156.88M
- Year Range
- $25.28 - $57.38
- Target Price
- $54.50
- ROA (TTM)
- 30.21%
- ROE (TTM)
- 79.21%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TGTX Performance Chart
TG Therapeutics, Inc. (TGTX) is up 82.5% since the beginning of the year. At $54 per share, TGTX is trading 5.2% below its 52-week high of $57. Investors who bought $1,000 worth of TGTX shares 5 years ago would now be looking at an investment worth $1,435.
Loading charts...
Returns By Period
TG Therapeutics, Inc. (TGTX) has returned 82.49% so far this year and 51.03% over the past 12 months. Looking at the last ten years, TGTX has achieved an annualized return of 24.56%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
TG Therapeutics, Inc.
- 1D
- 2.22%
- 1M
- 39.95%
- YTD
- 82.49%
- 6M
- 74.81%
- 1Y
- 51.03%
- 3Y*
- 32.10%
- 5Y*
- 7.49%
- 10Y*
- 24.56%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.15%
- 1Y
- 24.03%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
TGTX Monthly Returns History
Based on dividend-adjusted daily data since May 3, 2010, TGTX's average daily return is +0.50%, while the average monthly return is +3.58%. At this rate, an investment would double in approximately 1.6 years.
Historically, 49% of months were positive and 51% were negative. The best month was Jan 2012 with a return of +200.0%, while the worst month was Dec 2011 at -66.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, TGTX closed higher 44% of trading days. The best single day was Feb 6, 2012 with a return of +566.6%, while the worst single day was Jul 19, 2011 at -71.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.27% | 2.24% | 10.40% | 1.69% | 12.31% | 43.38% | 82.49% | ||||||
| 2025 | 5.32% | -5.08% | 31.04% | 15.42% | -22.85% | 2.51% | -1.36% | -17.38% | 23.17% | -3.72% | -4.37% | -10.37% | -0.96% |
| 2024 | -4.92% | 6.03% | -11.67% | -10.19% | 19.33% | 9.14% | 11.07% | 18.88% | -0.43% | 7.14% | 38.87% | -13.51% | 76.23% |
| 2023 | 28.74% | 5.19% | -6.12% | 65.09% | 7.25% | -6.72% | -16.71% | -49.40% | -20.15% | -7.54% | 65.72% | 33.33% | 44.38% |
| 2022 | -39.11% | -14.69% | -3.65% | -27.02% | -36.31% | -3.85% | 40.94% | 19.03% | -16.97% | -1.69% | 51.55% | 34.13% | -37.74% |
| 2021 | -7.21% | -9.32% | 10.12% | -7.24% | -22.01% | 11.24% | -9.80% | -22.64% | 22.94% | -6.19% | -51.31% | 25.00% | -63.48% |
Benchmark Metrics
TG Therapeutics, Inc. has an annualized alpha of 184.19%, beta of 1.57, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since May 03, 2010.
- This stock participated in 190.84% of S&P 500 Index downside but only 114.30% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 184.19%
- Beta
- 1.57
- R²
- 0.02
- Upside Capture
- 114.30%
- Downside Capture
- 190.84%
Return for Risk
Risk / Return Rank
TGTX ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TGTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.94 | ||
| Sortino ratioReturn per unit of downside risk | -1.01 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.37 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 1.57 | 2.78 | -1.21 |
| Martin ratioReturn relative to average drawdown | 2.84 | 12.44 | -9.60 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the TG Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TG Therapeutics, Inc. was 99.52%, occurring on Dec 29, 2011. The portfolio has not yet recovered.
The current TG Therapeutics, Inc. drawdown is 76.70%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2011 bear market2011 | -99.52%Dec 2011 | 1y 7mo | — | 16y 1moMay 2010 - now |
Drawdown Indicators
| TGTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.52% | -56.78% | -42.74% |
Max Drawdown (1Y)Largest decline over 1 year | -32.66% | -9.10% | -23.56% |
Max Drawdown (3Y)Largest decline over 3 years | -74.79% | -18.90% | -55.89% |
Max Drawdown (5Y)Largest decline over 5 years | -90.75% | -25.43% | -65.32% |
Max Drawdown (10Y)Largest decline over 10 years | -93.19% | -33.92% | -59.27% |
Current DrawdownCurrent decline from peak | -76.70% | -1.80% | -74.90% |
Average DrawdownAverage peak-to-trough decline | -91.41% | -10.71% | -80.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.03% | 2.03% | +16.00% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TG Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how TG Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TGTX, comparing it with other companies in the Biotechnology industry. Currently, TGTX has a P/E ratio of 18.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TGTX compared to other companies in the Biotechnology industry. TGTX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TGTX relative to other companies in the Biotechnology industry. Currently, TGTX has a P/S ratio of 12.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TGTX in comparison with other companies in the Biotechnology industry. Currently, TGTX has a P/B value of 14.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TGTX
Add TG Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TGTX